Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Cerecin Inc. operates within the Biotechnology & Pharmaceuticals technology area. The company currently faces 3 pending office actions. These actions are distributed across 3 distinct examiners and 3 distinct art units. This indicates a highly fragmented prosecution landscape where each matter is handled by a different individual and technical group within the USPTO. Such a distribution suggests that the portfolio's current legal challenges are spread across multiple specialized domains rather than being concentrated in a single area.
TIEN, LUCY MINYU is identified as the busiest examiner for this portfolio. However, this examiner is only responsible for 1 pending office action. This suggests that no single examiner holds a dominant share of the current workload. Practitioners should prepare for varied examination styles across the 3 distinct art units involved. Because each of the 3 distinct examiners is managing exactly one action, the prosecution strategy must be tailored to different sets of examiner preferences and technical interpretations simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TIEN, LUCY MINYU | 1 | 59.3% | +39.2% |
| VU, JAKE MINH | 1 | 41.1% | +27.2% |
| PATEL, SAGAR S | 1 | 75.7% | +34.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037681 | RADIOPHARMACEUTICAL KETONE AND DUAL TRACER IMAGING IN ALZHEIMER'S DISEASE, COGNITIVE IMPAIRMENT, AND OTHER CONDITIONS OF ALTERED CEREBRAL METABOLISM | VU, JAKE MINH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563204 | STABLE LIQUID PHARMACEUTICAL COMPOSITIONS HAVING HIGH DRUG LOADINGS OF MEDIUM CHAIN TRIGLYCERIDES AND METHODS RELATED THERETO | TIEN, LUCY MINYU | 97d overdue |
| 18037681 | RADIOPHARMACEUTICAL KETONE AND DUAL TRACER IMAGING IN ALZHEIMER'S DISEASE, COGNITIVE IMPAIRMENT, AND OTHER CONDITIONS OF ALTERED CEREBRAL METABOLISM | VU, JAKE MINH | — |
| 18248186 | METHODS FOR DELIVERING MEDIUM CHAIN TRIGLYCERIDES WITH CONTROLLED PHARMACOKINETIC, SAFETY AND TOLERABILITY PROFILES | PATEL, SAGAR S | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| 1618 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18563204 | STABLE LIQUID PHARMACEUTICAL COMPOSITIONS HAVING HIGH DRUG LOADINGS OF MEDIUM CHAIN TRIGLYCERIDES AND METHODS RELATED THERETO | TIEN, LUCY MINYU | 1612 | §103DP | Final Rejection | 97d overdue | Pending | Nov 21, 2023 |
| 18037681 | RADIOPHARMACEUTICAL KETONE AND DUAL TRACER IMAGING IN ALZHEIMER'S DISEASE, COGNITIVE IMPAIRMENT, AND OTHER CONDITIONS OF ALTERED CEREBRAL METABOLISM | VU, JAKE MINH | 1618 | §102§103§112 | Non-Final OA | — | Pending | May 18, 2023 |
| 18248186 | METHODS FOR DELIVERING MEDIUM CHAIN TRIGLYCERIDES WITH CONTROLLED PHARMACOKINETIC, SAFETY AND TOLERABILITY PROFILES | PATEL, SAGAR S | 1626 | §102 | Final Rejection | — | Pending | Apr 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial